한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제19권2호
  • /
  • Pages.75-80
  • /
  • 2009
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지

난소제거 흰쥐에서 단삼과 키토산 혼합물의 골다공증 개선효과

The Study of the Combination of Salvia Miltiorrhiza and Kitosan on Osteoporosis in Ovariectomized Rats

  • 김도성 (전북대학교 의과대학 약리학교실) ;
  • 한송희 (전북대학교 의과대학 약리학교실) ;
  • 이용철 (폐손상치료개발특성화 센터, 전북대학교 병원) ;
  • 박성주 (폐손상치료개발특성화 센터, 전북대학교 병원) ;
  • 류완희 (폐손상치료개발특성화 센터, 전북대학교 병원) ;
  • 김형룡 (원광대학교 치과대학 치과약리학교실) ;
  • 채한정 (전북대학교 의과대학 약리학교실)
  • Kim, Do-Sung (Department of Pharmacology, Medical School, Chonbuk National University) ;
  • Han, Song-Hee (Department of Pharmacology, Medical School, Chonbuk National University) ;
  • Lee, Yong-Chul (Research Center for Pulmonary Disorders, Chonbuk Hospital) ;
  • Park, Seong-Ju (Research Center for Pulmonary Disorders, Chonbuk Hospital) ;
  • Yoo, Wan-Hee (Research Center for Pulmonary Disorders, Chonbuk Hospital) ;
  • Kim, Hyung-Ryong (Department of Dental Pharmacology, College of Dentistry) ;
  • Chae, Han-Jung (Department of Pharmacology, Medical School, Chonbuk National University)
  • 투고 : 2009.07.01
  • 심사 : 2009.08.14
  • 발행 : 2009.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The preventive effect of Salvia miltiorrhiza extracts (SM) with or without high molecular weight soluble kitosan (K) on the progress of bone loss induced by ovariectomized (OVX) was studied in rats. From light microscopic analyses in histochemistry data, trabecular bone area in OVX rats was significantly decreased compared with that in sham rats. The decrease was regulated by administration of SM and especially the combination of SM and K (SM + K) for 7 weeks. In addition, the numbers of osteoblasts and osteoclasts were regulated in SM + K-administered rats but not different from those in either SM or K-administered rats. In OVX rats, free Triiodothyronine ($T_3$) and Thyroxine ($T_4$) were similar to control, ruling out the involvement of abnormal thyroid hormone. Although serum calcium is similar among all the groups, estrogen level was higher especially in SM+K-administered rats. These results strongly suggest that SM+K are effective in preventing the development of bone loss induced by OVX in rats.

키워드

참고문헌

  1. Sankaran SK. Osteoporosis prevention and treatment. Pharmacological management and treatment implications. Drugs Aging 1996; 9: 472-477. https://doi.org/10.2165/00002512-199609060-00009
  2. Schneider DL. Management of osteoporosis in geriatric populations. Curr Osteoporos Rep 2008; 6: 100-107. https://doi.org/10.1007/s11914-008-0018-4
  3. Miller PD. Anti-resorptives in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008; 22: 849-868. https://doi.org/10.1016/j.beem.2008.07.004
  4. Sibilia V and Netti C. Current therapies and future directions in osteoporosis management. Pharmacol Res 1996; 34: 237-245. https://doi.org/10.1006/phrs.1996.0094
  5. Han JY, Fan JY, Horie Y et al. Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol Ther 2008; 117: 280-295. https://doi.org/10.1016/j.pharmthera.2007.09.008
  6. Hu S, Chen SM, Li XK et al. Antitumor effects of chishen extract from Salvia miltiorrhiza and Paeoniae radix on human hepatocellular carcinoma cells. Acta Pharmacol Sin 2007; 28: 1215-1223. https://doi.org/10.1111/j.1745-7254.2007.00606.x
  7. Guo BL, Feng YX and Zhao YJ. Review of germplasm resources studies on Salvia miltiorrhiza. Zhongguo ZhongYao ZaZhi 2002; 27: 492-495.
  8. Chae HJ, Chae SW, Yun DH et al. Prevention of bone loss in ovariectomized rats: the effect of Salvia miltiorrhiza extracts. Immunopharmacol Immunotoxicol 2004; 26: 135-144. https://doi.org/10.1081/IPH-120029951
  9. Kwak HB, Yang D, Ha H et al. Tanshinone IIA inhibits osteoclast differentiation through down-regulation of c-Fos and NFATc1. Exp Mol Med 2006; 38: 256-264. https://doi.org/10.1038/emm.2006.31
  10. Kwak HB, Sun HM, Ha H et al. Tanshinone IIA suppresses inflammatory bone loss by inhibiting the synthesis of prostaglandin E2 in osteoblasts. Eur J Pharmacol 2008 28; 601: 30-37.
  11. Kim HK, Woo ER, Lee HW et al. The correlation of Salvia miltiorrhiza extract-induced regulation of osteoclastogenesis with the amount of components tanshinone I, tanshinone IIA, cryptotanshinone, and dihydrotanshinone. Immunopharmacol Immunotoxicol 2008; 30: 347-364. https://doi.org/10.1080/08923970801949133
  12. Gao Y, He L, Katsumi H et al. Improvement of intestinal absorption of insulin and water-soluble macromolecular compounds by chitosan oligomers in rats. Int J Pharm 2008; 359: 70-78. https://doi.org/10.1016/j.ijpharm.2008.03.016
  13. Chae HJ, Lee GY, Yang SK et al. Effect of high molecular weight water-soluble chitosan on the trabecular bone and thickness in ovariectomized rats. Immunopharmacol Immunotoxicol 2007; 29: 439-449. https://doi.org/10.1080/08923970701691140
  14. Lee JY, Choo JE, Choi YS et al. Effect of immobilized cell-binding peptides on chitosan membranes for osteoblastic differentiation of mesenchymal stem cells. Biotechnol Appl Biochem 2009; 52: 69-77. https://doi.org/10.1042/BA20070169
  15. Yamada S, Ohara N and Hayashi Y. Mineralization of matrix vesicles isolated from a human osteosarcoma cell line in culture with water-soluble chitosan-containing medium. J Biomed Mater Res A. 2003; 66(3):500-506.
  16. Nagasaka S, Sugimoto H, Nakamura T et al. Antithyroid therapy improves bony manifestations and bone metabolic markers in patients with Graves' thyrotoxicosis. Clin Endocrinol (Oxf) 1997; 47: 215-221. https://doi.org/10.1046/j.1365-2265.1997.2401045.x
  17. Zaidi M, Davies TF, Zallone A et al. Thyroid-stimulating hormone, thyroid hormones, and bone loss. Curr Osteoporos Rep 2009; 7: 47-52. https://doi.org/10.1007/s11914-009-0009-0
  18. Kalu DN, Liu CC, Hardin RR et al. The aged rat model of ovarian hormone deficiency bone loss. Endocrinology 1989; 124: 7-16. https://doi.org/10.1210/endo-124-1-7
  19. Chlebowski RT, Kuller LH, Prentice RL et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009; 360(6):573-587. https://doi.org/10.1056/NEJMoa0807684
  20. Anderson GL, Chlebowski RT, Rossouw JE et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006; 55(2):103-115. https://doi.org/10.1016/j.maturitas.2006.05.004